Robert L. Coleman

Dr. Coleman is a professor of gynecologic oncology and vice-chair of clinical research at The University of Texas MD Anderson Cancer Center in Houston, Texas. He is a world-renown expert who has distinguished himself as a key opinion leader in cancers of the female genital tract. As a key opinion leader, he is a frequently invited lecturer for national and international conferences and meetings where he continues to foster global scientific collaboration. He is the MD Anderson’s Gynecologic Oncology Group (GOG) Principal Investigator (PI) and is PI or Co-PI for several GOG prospective clinical trials including a national, multicenter, randomized trial evaluating chemotherapy and surgery for recurrent ovarian cancer, as well as, numerous investigator-initiated clinical studies of novel chemotherapeutic and biological compounds in cancers of the ovary, cervix, and uterus. Dr. Coleman was the Principal Investigator for the just completed Phase 2A clinical trial for EP-100 in patients with advanced ovarian cancer. He will continue to be the Principal Investigator for the proposed Phase 2B trial for EP-100.

Dr. Coleman has authored and co-authored over 400 scientific publications, including over 130 peer-reviewed articles, numerous book chapters, monographs, invited articles, and textbooks. He is a past President of the Society of Gynecologic Oncology. He currently serves on the Editorial Board of several peer-reviewed scientific publications. He is an active member of many national organizations including the Society of Gynecologic Oncology, the American College of Surgeons, the American Association for Cancer Research, and the American Society of Clinical Oncology.